121 related articles for article (PubMed ID: 35294890)
1. A hotspot mutation targeting the R-RAS2 GTPase acts as a potent oncogenic driver in a wide spectrum of tumors.
Fernández-Pisonero I; Clavaín L; Robles-Valero J; Lorenzo-Martín LF; Caloto R; Nieto B; García-Macías C; Oeste CL; Sánchez-Martín M; Abad A; Hortal A; Caballero D; González M; Dosil M; Alarcón B; Bustelo XR
Cell Rep; 2022 Mar; 38(11):110522. PubMed ID: 35294890
[TBL] [Abstract][Full Text] [Related]
2. Characterization of mutant versions of the R-RAS2/TC21 GTPase found in tumors.
Clavaín L; Fernández-Pisonero I; Movilla N; Lorenzo-Martín LF; Nieto B; Abad A; García-Navas R; Llorente-González C; Sánchez-Martín M; Vicente-Manzanares M; Santos E; Alarcón B; García-Aznar JM; Dosil M; Bustelo XR
Oncogene; 2023 Jan; 42(5):389-405. PubMed ID: 36476833
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of wild type RRAS2, without oncogenic mutations, drives chronic lymphocytic leukemia.
Hortal AM; Oeste CL; Cifuentes C; Alcoceba M; Fernández-Pisonero I; Clavaín L; Tercero R; Mendoza P; Domínguez V; García-Flores M; Pintado B; Abia D; García-Macías C; Navarro-Bailón A; Bustelo XR; González M; Alarcón B
Mol Cancer; 2022 Feb; 21(1):35. PubMed ID: 35120522
[TBL] [Abstract][Full Text] [Related]
4. The RRAS2 pathogenic variant p.Q72L produces severe Noonan syndrome with hydrocephalus: A case report.
Weinstock NI; Sadler L
Am J Med Genet A; 2022 Jan; 188(1):364-368. PubMed ID: 34648682
[TBL] [Abstract][Full Text] [Related]
5. R-RAS2 overexpression in tumors of the human central nervous system.
Gutierrez-Erlandsson S; Herrero-Vidal P; Fernandez-Alfara M; Hernandez-Garcia S; Gonzalo-Flores S; Mudarra-Rubio A; Fresno M; Cubelos B
Mol Cancer; 2013 Oct; 12(1):127. PubMed ID: 24148564
[TBL] [Abstract][Full Text] [Related]
6. Activating Mutations of RRAS2 Are a Rare Cause of Noonan Syndrome.
Capri Y; Flex E; Krumbach OHF; Carpentieri G; Cecchetti S; Lißewski C; Rezaei Adariani S; Schanze D; Brinkmann J; Piard J; Pantaleoni F; Lepri FR; Goh ES; Chong K; Stieglitz E; Meyer J; Kuechler A; Bramswig NC; Sacharow S; Strullu M; Vial Y; Vignal C; Kensah G; Cuturilo G; Kazemein Jasemi NS; Dvorsky R; Monaghan KG; Vincent LM; Cavé H; Verloes A; Ahmadian MR; Tartaglia M; Zenker M
Am J Hum Genet; 2019 Jun; 104(6):1223-1232. PubMed ID: 31130282
[TBL] [Abstract][Full Text] [Related]
7. Contribution of the R-Ras2 GTP-binding protein to primary breast tumorigenesis and late-stage metastatic disease.
Larive RM; Moriggi G; Menacho-Márquez M; Cañamero M; de Álava E; Alarcón B; Dosil M; Bustelo XR
Nat Commun; 2014 May; 5():3881. PubMed ID: 24826867
[TBL] [Abstract][Full Text] [Related]
8. The RRAS2 pathogenic variant (c.67G>T; p. Gly23Cys) produces Noonan syndrome with embryonal rhabdomyosarcoma.
Zeng L; Wang J; Zhu H; Huang Y; Deng Y; Wei P; Nie J; Tang B; Chen A; Zhu S
Mol Genet Genomic Med; 2024 Jan; 12(1):e2313. PubMed ID: 37942564
[TBL] [Abstract][Full Text] [Related]
9. The ancestral type of the R-RAS protein has oncogenic potential.
Talajić A; Dominko K; Lončarić M; Ambriović-Ristov A; Ćetković H
Cell Mol Biol Lett; 2024 Feb; 29(1):27. PubMed ID: 38383288
[TBL] [Abstract][Full Text] [Related]
10. Clinical analysis of Noonan syndrome caused by RRAS2 mutations and literature review.
Yu C; Lyn N; Li D; Mei S; Liu L; Shang Q
Eur J Med Genet; 2023 Jan; 66(1):104675. PubMed ID: 36460282
[TBL] [Abstract][Full Text] [Related]
11. Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia.
Pomeroy EJ; Lee LA; Lee RDW; Schirm DK; Temiz NA; Ma J; Gruber TA; Diaz-Flores E; Moriarity BS; Downing JR; Shannon KM; Largaespada DA; Eckfeldt CE
Oncogene; 2017 Jun; 36(23):3263-3273. PubMed ID: 27991934
[TBL] [Abstract][Full Text] [Related]
12. The Ras-like protein R-Ras2/TC21 is important for proper mammary gland development.
Larive RM; Abad A; Cardaba CM; Hernández T; Cañamero M; de Álava E; Santos E; Alarcón B; Bustelo XR
Mol Biol Cell; 2012 Jun; 23(12):2373-87. PubMed ID: 22535521
[TBL] [Abstract][Full Text] [Related]
13. Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells.
Yuen HF; Abramczyk O; Montgomery G; Chan KK; Huang YH; Sasazuki T; Shirasawa S; Gopesh S; Chan KW; Fennell D; Janne P; El-Tanani M; Murray JT
Biosci Rep; 2012 Aug; 32(4):413-22. PubMed ID: 22668349
[TBL] [Abstract][Full Text] [Related]
14. Role of TC21/R-Ras2 in enhanced migration of neurofibromin-deficient Schwann cells.
Huang Y; Rangwala F; Fulkerson PC; Ling B; Reed E; Cox AD; Kamholz J; Ratner N
Oncogene; 2004 Jan; 23(2):368-78. PubMed ID: 14724565
[TBL] [Abstract][Full Text] [Related]
15. CBAP modulates Akt-dependent TSC2 phosphorylation to promote Rheb-mTORC1 signaling and growth of T-cell acute lymphoblastic leukemia.
Chiang YJ; Liao WT; Ho KC; Wang SH; Chen YG; Ho CL; Huang SF; Shih LY; Yang-Yen HF; Yen JJ
Oncogene; 2019 Feb; 38(9):1432-1447. PubMed ID: 30266989
[TBL] [Abstract][Full Text] [Related]
16. R-Ras1 and R-Ras2 Are Essential for Oligodendrocyte Differentiation and Survival for Correct Myelination in the Central Nervous System.
Sanz-Rodriguez M; Gruart A; Escudero-Ramirez J; de Castro F; Delgado-García JM; Wandosell F; Cubelos B
J Neurosci; 2018 May; 38(22):5096-5110. PubMed ID: 29720552
[TBL] [Abstract][Full Text] [Related]
17. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.
Yuen HF; Chan KK; Grills C; Murray JT; Platt-Higgins A; Eldin OS; O'Byrne K; Janne P; Fennell DA; Johnston PG; Rudland PS; El-Tanani M
Clin Cancer Res; 2012 Jan; 18(2):380-91. PubMed ID: 22090358
[TBL] [Abstract][Full Text] [Related]
18. Biochemical characterization of yeast RAS2 mutants reveals a new region of ras protein involved in the interaction with GTPase-activating proteins.
Wood DR; Poullet P; Wilson BA; Khalil M; Tanaka K; Cannon JF; Tamanoi F
J Biol Chem; 1994 Feb; 269(7):5322-7. PubMed ID: 8106517
[TBL] [Abstract][Full Text] [Related]
19. R-Ras2 is required for germinal center formation to aid B cells during energetically demanding processes.
Mendoza P; Martínez-Martín N; Bovolenta ER; Reyes-Garau D; Hernansanz-Agustín P; Delgado P; Diaz-Muñoz MD; Oeste CL; Fernández-Pisonero I; Castellano E; Martínez-Ruiz A; Alonso-Lopez D; Santos E; Bustelo XR; Kurosaki T; Alarcón B
Sci Signal; 2018 May; 11(532):. PubMed ID: 29844052
[TBL] [Abstract][Full Text] [Related]
20. Farnesyltransferase inhibitors are inhibitors of Ras but not R-Ras2/TC21, transformation.
Carboni JM; Yan N; Cox AD; Bustelo X; Graham SM; Lynch MJ; Weinmann R; Seizinger BR; Der CJ; Barbacid M
Oncogene; 1995 May; 10(10):1905-13. PubMed ID: 7761092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
